GlassScriptPhysician profile
Jill Flury
NPI 1639226285
$2,806.86
in general payments reported to CMS, 2019-2025
22 companies · $584 in 2025
The $584 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $444 · 2022: $330 · 2023: $518 · 2024: $931 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.96 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.64 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $405.04 | 2021-2024 | Ajovy, Austedo Xr |
| Tempus Ai, INC | $276.91 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Janssen Pharmaceuticals, INC | $205.04 | 2024-2025 | Spravato |
| Amgen INC. | $189.05 | 2021-2023 | Aimovig |
| Lundbeck LLC | $152.87 | 2021-2024 | Vyepti |
| Lilly USA, LLC | $144.40 | 2021-2024 | Emgality |
| Takeda Pharmaceuticals U.S.A., INC. | $124.59 | 2023-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $78.54 | 2023-2025 | Qelbree, Qelbree |
| Biohaven Pharmaceuticals, INC. | $73.63 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.12 | 2022 | |
| Upsher-Smith Laboratories LLC | $61.66 | 2021-2023 | |
| Pfizer INC. | $55.31 | 2023-2024 | |
| Biotronik Nro, INC. | $53.01 | 2025 | Prospera |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.13 | 2023-2024 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $36.13 | 2023-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $23.38 | 2025 | Cobenfy |
| Impel Pharmaceuticals LLC | $22.46 | 2025 | Trudhesa |
| Tonix Medicines, INC. | $20.99 | 2025 | Zembrace Symtouch |
| Kowa Pharmaceuticals America, INC. | $19.65 | 2023 | Seglentis |
| Allergan, INC. | $19.39 | 2021 | |
| Axsome Therapeutics, INC. | $15.92 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Flury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.